Clinical Trials | May 08, 2026
Moderna’s mRNA flu vaccine outperforms standard shot in Phase 3 trial
NEJM study shows strong protection across strains
NEJM study shows strong protection across strains
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The company says the platform offers improved manufacturability and functional advantages
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
The company plans to submit the vaccine for regulatory review
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
The order will cover the manufacturing of bulk vaccine in 2026
Subscribe To Our Newsletter & Stay Updated
